Docket No. 2609/68811-A/JPW/GJG/MML

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Sharon Cohen-Vered et al.

Serial No. : 10/758,397

Filed : January 14, 2004

Title : PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS

1185 Avenue of the Americas
New York, New York 10036
September 10, 2004

MAIL STOP Sequence
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

AMENDMENT IN RESPONSE TO AUGUST 12, 2004
NOTICE TO FILE MISSING PARTS OF APPLICATION FILING DATE GRANTED

This Communication is submitted in response to the August 12, 2004 Notice to File Missing Parts issued by the United States Patent and Trademark Office in connection with the above-identified application. A copy of this Notice is attached as **Exhibit A.** A response to the August 12, 2004 is due October 12, 2004. Therefore, this Communication is being timely filed.

Please amend the subject application as follows:

Please insert the paper copy of the "Sequence Listing" attached hereto as **Exhibit C** after the Abstract of the subject application.

In addition, please amend the paragraph appearing on page 7, lines 1-8 as follows:

> Human CDR1, Shown in Figure 1, is a synthetic peptide of 19 amino acids based on the complementarity-determining region 1 (CDR1) of the human anti-dsDNA mAb denoted 16/6 Id, (SEQ ID NO: 18) (Waisman, A., et al. "Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of pathogenic anti-DNA monoclonal antibodies." *Proc. Natl. Acad. Sci. U.S.A.* (1997), 94(4):4620-4625.

Please also amend the paragraph appearing on page 7, lines 3-4 as follows:

> **Figure 1.** Human CDR1 (Compound 1) as acetate salt - showing the molecular and structural formulas of hCDR1, the amino acid sequence, (SEQ ID NO:18) and physical parameters.